Researchers at Rensselaer and Albany Medical Center are working together to develop three-dimensional bioprinting and imaging techniques that will generate and analyze tumor models in the laboratory, with the goal of accelerating the development and optimization of personalized anti-cancer drugs. The joint research, supported by a $3.7 million grant from the National Cancer Institute, will help address fundamental issues in cancer research and treatment.“If successful, our study will help researchers to develop personalized anti-cancer treatments,” said David Corr, one of the study’s principal investigators and Rensselaer associate professor of biomedical engineering. “Ultimately, this research could help clinicians identify whether a particular drug, or drug combination, is effectively reaching the cancer cells in that type of tumor, in that specific person—to inform a patient-specific treatment strategy prior to undergoing chemotherapy.”